D. E. Shaw & Co., Inc. Chinook Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$18.66 - $38.58 $700,720 - $1.45 Million	-37,552 Reduced 11.75%	282,154 $10.8 Million
Q1 2023 May 15, 2023	SELL	$21.53 - $26.8 $862,900 - $1.07 Million	-40,079 Reduced 11.14%	319,706 $7.4 Million
Q4 2022 Feb 14, 2023	SELL	$18.63 - $27.35 $2.23 Million - $3.27 Million	-119,742 Reduced 24.97%	359,785 $9.43 Million
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $3.96 Million - $5.28 Million	225,945 Added 89.1%	479,527 $9.43 Million
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $2.41 Million - $3.59 Million	191,135 Added 306.08%	253,582 $4.44 Million
Q1 2022 May 16, 2022	SELL	$12.02 - $16.69 $789,173 - $1.1 Million	-65,655 Reduced 51.25%	62,447 $1.02 Million
Q4 2021 Feb 14, 2022	BUY	$10.69 - $16.83 $1.03 Million - $1.62 Million	95,966 Added 298.62%	128,102 $2.09 Million
Q3 2021 Nov 15, 2021	BUY	$11.5 - $14.86 $369,564 - $477,540	32,136 New	32,136 $410,000
Q1 2021 May 17, 2021	SELL	$14.17 - $19.11 $506,379 - $682,914	-35,736 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$11.9 - $20.91 $425,258 - $747,239	35,736 New	35,736 $567,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.